From c630c34e3ee658bcc206930ba59589178bb10cd1 Mon Sep 17 00:00:00 2001 From: m3taversal Date: Wed, 18 Mar 2026 14:53:40 +0000 Subject: [PATCH] =?UTF-8?q?leo:=20resolve=20merge=20conflict=20=E2=80=94?= =?UTF-8?q?=20apply=20GLP-1=20lifestyle=20modification=20enrichments=20to?= =?UTF-8?q?=20post-restructure=20main?= MIME-Version: 1.0 Content-Type: text/plain; charset=UTF-8 Content-Transfer-Encoding: 8bit - What: Cherry-picked lifestyle+exercise enrichments, resolved conflicts with WHO GLP-1 enrichments (both kept) - Why: Epimetheus archive restructure + parallel WHO enrichment merge caused conflicts Pentagon-Agent: Leo --- ...t cost impact inflationary through 2035.md | 5 ++++ ...ients-undermining-chronic-use-economics.md | 5 ++++ ...dification-efficacy-combined-approach.json | 25 +++++++++++++++++++ ...modification-efficacy-combined-approach.md | 15 ++++++++++- 4 files changed, 49 insertions(+), 1 deletion(-) create mode 100644 inbox/archive/.extraction-debug/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.json diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index bf3d05709..9141c89a5 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -89,6 +89,11 @@ BALANCE Model's dual payment mechanism (capitation adjustment + reinsurance) plu WHO's conditional recommendation structure and behavioral therapy requirement suggest the 'chronic use model' framing may be incomplete. The guideline establishes medication-plus-behavioral-therapy as the standard, not medication alone, which may have different economics than the pure pharmaceutical model. WHO also announced it will develop 'an evidence-based prioritization framework to identify which adults with obesity should be prioritized for GLP-1 treatment'—implying targeted use rather than universal chronic treatment. +### Additional Evidence (challenge) +*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-18* + +If GLP-1+exercise creates durable behavioral change that persists after medication stops (3.5kg regain vs 8.7kg for medication alone), then the chronic use assumption may be wrong. The optimal economic model might be time-limited GLP-1 as a catalyst for behavior change, not lifetime medication. This would dramatically reduce the inflationary cost trajectory if lifestyle support infrastructure can scale. + --- Relevant Notes: diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 40852332c..1392cb714 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -77,6 +77,11 @@ BALANCE Model's manufacturer-funded lifestyle support requirement directly addre WHO's conditional recommendation requiring behavioral therapy combination provides international regulatory support for adherence interventions. The guideline explicitly states GLP-1s should be 'combined with intensive behavioral therapy to maximize and sustain benefits'—directly addressing the persistence problem by making behavioral support the standard of care rather than an optional add-on. +### Additional Evidence (extend) +*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-18* + +Weight regain data shows that even among patients who complete treatment courses, GLP-1 alone produces 8.7kg regain vs 3.5kg for GLP-1+exercise by week 104 post-discontinuation. This means the persistence problem has two layers: patients stop taking the drug (15% continuation at 2 years), AND those who complete treatment cycles regain weight unless exercise is part of the intervention. The economic model must account for both discontinuation losses and post-treatment regain. + --- Relevant Notes: diff --git a/inbox/archive/.extraction-debug/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.json b/inbox/archive/.extraction-debug/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.json new file mode 100644 index 000000000..1182a1d2a --- /dev/null +++ b/inbox/archive/.extraction-debug/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.json @@ -0,0 +1,25 @@ +{ + "rejected_claims": [ + { + "filename": "glp-1-combined-with-structured-exercise-achieves-substantially-better-weight-maintenance-than-medication-alone-suggesting-behavioral-change-outlasts-pharmacotherapy.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 1, + "kept": 0, + "fixed": 2, + "rejected": 1, + "fixes_applied": [ + "glp-1-combined-with-structured-exercise-achieves-substantially-better-weight-maintenance-than-medication-alone-suggesting-behavioral-change-outlasts-pharmacotherapy.md:set_created:2026-03-18", + "glp-1-combined-with-structured-exercise-achieves-substantially-better-weight-maintenance-than-medication-alone-suggesting-behavioral-change-outlasts-pharmacotherapy.md:stripped_wiki_link:glp-1-persistence-drops-to-15-percent-at-two-years-for-non-d" + ], + "rejections": [ + "glp-1-combined-with-structured-exercise-achieves-substantially-better-weight-maintenance-than-medication-alone-suggesting-behavioral-change-outlasts-pharmacotherapy.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-18" +} \ No newline at end of file diff --git a/inbox/queue/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md b/inbox/queue/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md index 3c5435d24..199e69f23 100644 --- a/inbox/queue/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md +++ b/inbox/queue/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md @@ -7,9 +7,13 @@ date: 2026-03-01 domain: health secondary_domains: [] format: review -status: unprocessed +status: enrichment priority: high tags: [glp-1, lifestyle-modification, exercise, sarcopenia, muscle-preservation, adherence, weight-regain, obesity] +processed_by: vida +processed_date: 2026-03-18 +enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -75,3 +79,12 @@ Synthesis of 2025-2026 research on combining lifestyle modifications (diet, exer PRIMARY CONNECTION: GLP-1 cost-effectiveness under capitation requires solving the adherence paradox (March 12 claim candidate) WHY ARCHIVED: The "exercise is the active ingredient for weight maintenance" finding significantly changes how to evaluate BALANCE model design and GLP-1 economic models under VBC EXTRACTION HINT: Focus on the GLP-1 alone vs. GLP-1+exercise regain comparison — this is the claim-worthy finding. Also note the BALANCE model design needs evaluation against this evidence. + + +## Key Facts +- WHO December 2025 guidelines recommend GLP-1 therapies 'combined with intensive behavioral therapy to maximize and sustain benefits' +- Meta-analysis of 22 RCTs with 2,258 participants found ~25% of GLP-1 weight loss is lean mass +- Without exercise, 15-40% of GLP-1 weight loss is lean mass; with resistance training, lean mass loss is substantially reduced +- Up to half of adults over 80 experience sarcopenia; aging reduces muscle mass 12-16% baseline +- Tirzepatide may have better muscle preservation profile than semaglutide (preliminary data) +- No FDA-approved GLP-1 compounds with proven muscle preservation claims yet -- 2.45.2